We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novartis Loses Patent on Billion-Dollar MS Drug Following Circuit Court Appeal
Novartis Loses Patent on Billion-Dollar MS Drug Following Circuit Court Appeal
A federal appeals court upheld that a Novartis patent for its multibillion-dollar MS drug Gilenya is invalid, opening the door for generics as early as 2019.